161 related articles for article (PubMed ID: 35422085)
1. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
[TBL] [Abstract][Full Text] [Related]
2. Soy isoflavone genistein inhibits hsa_circ_0031250/miR-873-5p/FOXM1 axis to suppress non-small-cell lung cancer progression.
Yu Y; Xing Y; Zhang Q; Zhang Q; Huang S; Li X; Gao C
IUBMB Life; 2021 Jan; 73(1):92-107. PubMed ID: 33159503
[TBL] [Abstract][Full Text] [Related]
3. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
4. Thiostrepton confers protection against reactive oxygen species-related apoptosis by restraining FOXM1-triggerred development of gastric cancer.
Liu SX; Zhou Y; Zhao L; Zhou LS; Sun J; Liu GJ; Du YS; Zhou YN
Free Radic Biol Med; 2022 Nov; 193(Pt 1):385-404. PubMed ID: 36152915
[TBL] [Abstract][Full Text] [Related]
5. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
6. FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Xu N; Zhang X; Wang X; Ge HY; Wang XY; Garfield D; Yang P; Song YL; Bai CX
Acta Pharmacol Sin; 2012 May; 33(5):675-81. PubMed ID: 22447226
[TBL] [Abstract][Full Text] [Related]
7. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
8. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
11. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.
Li X; Yao R; Yue L; Qiu W; Qi W; Liu S; Yao Y; Liang J
J Cell Mol Med; 2014 May; 18(5):811-23. PubMed ID: 24628949
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
[TBL] [Abstract][Full Text] [Related]
15. MED28 and forkhead box M1 (FOXM1) mediate matrix metalloproteinase 2 (MMP2)-dependent cellular migration in human nonsmall cell lung cancer (NSCLC) cells.
Hsieh NT; Huang CY; Li CC; Wang IC; Lee MF
J Cell Physiol; 2019 Jul; 234(7):11265-11275. PubMed ID: 30499104
[TBL] [Abstract][Full Text] [Related]
16. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
18. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between expression of forkhead box M1 (FOXM1) and clinicopathological features and prognosis in patients with non-small cell lung cancer (NSCLC)].
Liu YQ; Guo RH; Liu LK; Gao W; Zhu CJ; Wei J; Shu YQ
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):426-30. PubMed ID: 21875482
[TBL] [Abstract][Full Text] [Related]
20. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
Xie T; Geng J; Wang Y; Wang L; Huang M; Chen J; Zhang K; Xue L; Liu X; Mao X; Chen Y; Wang Q; Dai T; Ren L; Yu H; Wang R; Chen L; Chen C; Chu X
Oncotarget; 2017 Jan; 8(5):8574-8589. PubMed ID: 28051999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]